Bibliographic citations
This is an automatically generated citacion. Modify it if you see fit
Avila, A., (2021). Infección respiratoria severa por SARS-COV-2: rol del receptor ECA2 [Tesis, Universidad Privada Antenor Orrego - UPAO]. https://hdl.handle.net/20.500.12759/7171
Avila, A., Infección respiratoria severa por SARS-COV-2: rol del receptor ECA2 [Tesis]. PE: Universidad Privada Antenor Orrego - UPAO; 2021. https://hdl.handle.net/20.500.12759/7171
@misc{renati/373522,
title = "Infección respiratoria severa por SARS-COV-2: rol del receptor ECA2",
author = "Avila Nureña, Alvaro Emerson",
publisher = "Universidad Privada Antenor Orrego - UPAO",
year = "2021"
}
Title: Infección respiratoria severa por SARS-COV-2: rol del receptor ECA2
Authors(s): Avila Nureña, Alvaro Emerson
Advisor(s): Llique Diaz, Walter Nicanor
Keywords: SRAS; Infección por coronavirus; Angiotensina II
OCDE field: http://purl.org/pe-repo/ocde/ford#3.01.03
Issue Date: 2021
Institution: Universidad Privada Antenor Orrego - UPAO
Abstract: El virus SARS-CoV-2, es responsable de la pandemia de la enfermedad COVID-19
y tiene como principal receptor a ECA2 un octopéptido con actividad vasoconstrictora
presente en las células del huésped, este receptor es clave para la entrada de SARS‐
CoV‐2 y se sugiere que también actúa como factor limitante para la entrada viral en
la etapa inicial de la infección. Para la realización de este estudio se hizo una
búsqueda de literatura en Pubmed/Medline, Scopus, Scient Direct y BVS donde se
evaluaron artículos de revisión y originales, en idiomas inglés y español, haciendo
referencia al tema de estudio a través del título. Como resultado se obtuvo 153
documentos en PUBMED y 450 en BVS de ellos nos quedamos con 70 artículos
relevantes. La conclusión a la que se llegó fue: La COVID-19 cuenta con 3 estadios
clínicos con respuesta inmune variada, por lo tanto, el tratamiento de esta
enfermedad depende del estadio clínico en el que se encuentra el paciente, la
infectividad en la COVID-19 está relacionada a la carga viral, las mutaciones que va
sufriendo este virus ayudan a fortalecer aún más su capacidad infectiva, El SARSCoV-2 se une a la ECA2, la fusión celular se da mediante la unión de la proteína S
con el receptor en la superficie de la célula huésped iniciando todo el curso infeccioso
y clínico de la COVID-19, ECA2 se encuentra en la membrana de las células
epiteliales de las vías respiratorias en su mayoría en los neumocitos tipo II,
constituyen el punto de entrada del SARS-CoV-2, la expresión de ECA y ECA2 en
las células epiteliales bronquiales aumentó significativamente en sujetos infectados
con la COVID‐19 que padecen EPOC, existen 4 mecanismo fisiopatológicos
asociados a ECA2 los cuales al magnificarse producen una mayor severidad de esta
enfermedad.
The SARS-CoV-2 virus is responsible for the COVID-19 disease pandemic and its main receptor for ECA2 is an octopeptide with vasoconstrictor activity present in host cells, this receptor is key for the entry of SARS-CoV- 2 and it is suggested that it also acts as a limiting factor for viral entry in the initial stage of infection. To carry out this study, a literature search was carried out in Pubmed / Medline, Scopus, Scient Direct and BVS, where review articles and originals were evaluated, in English and Spanish, referring to the study topic through the title. As a result, 153 documents were obtained in PUBMED and 450 in BVS, of which we were left with 70 relevant articles. The conclusion reached was: COVID-19 has 3 clinical stages with a varied immune response, therefore, the treatment of this disease depends on the clinical stage in which the patient is, infectivity in COVID- 19 is related to viral load, the mutations that this virus undergoes help to further strengthen its infective capacity, SARS-CoV-2 binds to ECA2, cell fusion occurs through the union of protein S with the receptor on the surface of the host cell initiating the entire infectious and clinical course of COVID-19, ECA2 is found in the membrane of the epithelial cells of the airways, mostly in type II pneumocytes, they constitute the entry point of the SARS-CoV-2, the expression of ACE and ACE2 in bronchial epithelial cells increased significantly in subjects infected with COVID-19 who suffer from COPD, there are 4 pathophysiological mechanisms associated with ACE2 which, when magnified, produce a greater severity of this disease.
The SARS-CoV-2 virus is responsible for the COVID-19 disease pandemic and its main receptor for ECA2 is an octopeptide with vasoconstrictor activity present in host cells, this receptor is key for the entry of SARS-CoV- 2 and it is suggested that it also acts as a limiting factor for viral entry in the initial stage of infection. To carry out this study, a literature search was carried out in Pubmed / Medline, Scopus, Scient Direct and BVS, where review articles and originals were evaluated, in English and Spanish, referring to the study topic through the title. As a result, 153 documents were obtained in PUBMED and 450 in BVS, of which we were left with 70 relevant articles. The conclusion reached was: COVID-19 has 3 clinical stages with a varied immune response, therefore, the treatment of this disease depends on the clinical stage in which the patient is, infectivity in COVID- 19 is related to viral load, the mutations that this virus undergoes help to further strengthen its infective capacity, SARS-CoV-2 binds to ECA2, cell fusion occurs through the union of protein S with the receptor on the surface of the host cell initiating the entire infectious and clinical course of COVID-19, ECA2 is found in the membrane of the epithelial cells of the airways, mostly in type II pneumocytes, they constitute the entry point of the SARS-CoV-2, the expression of ACE and ACE2 in bronchial epithelial cells increased significantly in subjects infected with COVID-19 who suffer from COPD, there are 4 pathophysiological mechanisms associated with ACE2 which, when magnified, produce a greater severity of this disease.
Link to repository: https://hdl.handle.net/20.500.12759/7171
Discipline: Medicina Humana
Grade or title grantor: Universidad Privada Antenor Orrego. Facultad de Medicina Humana
Grade or title: Médico Cirujano
Register date: 1-Feb-2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.